Phase I multiple-dose safety, pharmacokinetic, and pharmacodynamic clinical study of nitric oxide releasing aspirin (NCX-4016)
Phase of Trial: Phase I
Latest Information Update: 18 Jun 2007
At a glance
- Drugs NCX 4016 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Biomarker
- 31 Aug 2018 Biomarkers information updated
- 18 Jun 2007 Status changed from recruiting to discontinued.
- 05 Oct 2006 New trial record.